Arecor Therapeutics plc AIM:AREC
- Incorporated
- United Kingdom
- Chief executive
- Sarah Howell
- Employees
- 33
- Reports in
- GBP
- Companies House
- 13331147
Read straight from the annual reports
72.5p at close on 5 Oct 2026 · 6 reported years, 2020–2025
| Line | FY202012/20 | FY202112/21 | FY202212/22 | FY202312/23 | FY202412/24 | FY202512/25 | FY2026unreported |
|---|---|---|---|---|---|---|---|
| Revenue | |||||||
| Gross profit | — | — | — | ||||
| Operating profit | |||||||
| Adjusted operating profit | — | — | — | — | |||
| Exceptional items | — | ||||||
| Net finance cost | |||||||
| Profit before tax | |||||||
| Adjusted profit before tax | — | — | — | — | |||
| Tax charge | |||||||
| Profit for the year | |||||||
| EBITDA | |||||||
| Adjusted minus statutory PBT | — | — | — | — | |||
| Basic EPS | |||||||
| Diluted EPS | |||||||
| Dividend per share | — | — | — |
GBP millions, negatives in brackets. Per-share lines in pence, share counts in millions. later is what a following report restated the figure to; vs is a second reading that disagrees. The figure shown is the one the original filing printed, and both readings are kept. Click any figure: opens the report page it was read from, highlighted; shows how it was calculated. The share price above is drawn to the same columns: each close sits over the financial year it fell in.
6 years, at a glance
Dashed: Operating margin, in % on its own scale — read its shape, not its height against the bars.
Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupidatat non proident, sunt in culpa qui officia deserunt mollit anim id est laborum. Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.
Arestat formulation development collaborations with pharma/biotech partners (pre-license revenue)
Three new Arestat formulation development collaborations signed in 2025 (incl. Skye Bioscience) with total pre-license revenue of over £1 million
page 7Licence and royalty income from partnered products
Partner revenue for continuing operations increased to £1.7 million (2024: £1.6 million), of which £0.6 million was non-repeating royalty revenue
page 16Cessation of Tetris Pharma operations removing cost and cashburn
Cessation of operations at Tetris Pharma removed cost and cashburn from the business during 2025
page 5Gain on sale of royalty rights (Ligand transaction)
Gain-on-sale of intangible assets of £4,968k drove other operating income to £5.5 million (2024: £0.3 million) and operating profit of £0.9m vs prior year loss of £5.2m
page 72£5.0m credit: Gain on sale of royalty rights and technology access fees (Ligand transaction)
page 72Positive negotiations are in progress on a broader co-development and commercialisation partnership for the Phase 2 trial and beyond and are a current key focus for management. The Board has a high level of conviction in Arecor's focussed strategy.
page 6Formal Note 31 assessment: management identified no adjusting or non-adjusting post balance sheet events requiring disclosure
page 89The Directors do not recommend the payment of a dividend for 2025 (2024: £nil); no dividends paid or approved during the year
page 47Auditor (PKF Littlejohn LLP) issued an unmodified opinion but drew attention to a material uncertainty related to going concern (note 3): the Group has incurred net operating losses since inception except FY25 and expects further losses; base-case cash flow forecasts show the Group and parent will need to raise additional funding in or before Q2 2027, with a worst-case scenario requiring funding by April 2027. Key audit matters were (1) accounting for the gain on sale of royalty rights and associated deferred consideration and (2) valuation of parent-company intercompany loans receivable
page 51- Clinical & regulatory - early-stage development, highly regulated FDA/MHRA approval processes, risk of delays in timelines and patient recruitmentp.18
- Co-development - delay or inability to sign a co-development deal with an insulin device company would weaken ability to enter Phase 2p.18
- Technology & innovation - relatively low technology and innovation spend compared to larger competitorsp.18
- Intellectual property - competitors may seek to develop and commercialise similar products despite Arecor's patent portfoliop.18
Read from C000091-AR-2025-ch.
5 annual reports read, FY2021 to FY2025
Open a year to see what its report said. Every line in it carries the page it was read from.
Sources: Companies House (5)
FY2026Next report expected 29 Apr 2027